Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Colorectal Carcinoma

Colorectal Carcinoma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Colorectal Carcinoma

31 trials tracked for Colorectal Carcinoma: 6 in phase 3 or 4 and 5 with published results. The most-cited published study has 3162 citations.

31Trials tracked
6Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 1 Phase 3 5 Phase 2 12 Phase 1 5 Other / NA 8
  1. Phase 3 Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Completed · 3,162 cited
  2. Phase 3 BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma Completed · 174 cited
  3. Phase 3 Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults. Completed · 116 cited
  4. Phase 3 Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults Completed · 98 cited
  5. Phase 3 Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults. Completed
  6. Phase 4 Improvement of Fluid Balance in Patients Undergoing Surgery of the Colon and Rectum Completed
Show 25 more trials
  1. Phase 2 A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment Completed
  2. Phase 2 ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer Completed
  3. Phase 2 An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread Completed
  4. Phase 2 A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer Completed
  5. Phase 2 Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers Completed
  6. Phase 2 A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer Completed
  7. Phase 2 A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Completed
  8. Phase 2 Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer Completed
  9. Phase 2 Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma Completed
  10. Phase 2 Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma Completed
  11. Phase 2 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib Completed
  12. Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Completed
  13. Phase 1 A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) Completed
  14. Phase 1 Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers Completed
  15. Phase 1 Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening Completed
  16. Phase 1 AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer Completed
  17. Phase 1 Safety Study of PLX4032 in Patients With Solid Tumors Completed
  18. N/A Optimization of Adaptive Text Messages for Cancer Survivors (OATS II) Completed
  19. N/A Legume Diet Satiety Pilot Study Completed
  20. N/A Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma Completed
  21. N/A Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy Completed
  22. N/A EXERCISING TOGETHER for Couples Coping With Cancer Completed
  23. N/A Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC Completed
  24. N/A FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer Completed
  25. N/A Audio and Video Brochures for Increasing Colorectal Cancer Screening Among Adults Living in Appalachia Completed

Showing the 31 most-cited and recently-updated of 31 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Colorectal Carcinoma: what the trials found

In metastatic colorectal cancer, the phase 3 trial of mFOLFOX6 demonstrated significant improvements in progression-free survival (16.5 vs. 8.2 months, p=0.0001), overall survival (not reached vs. 36.7 months, p=0.0359), and overall response rate (45.1% vs. 33.1%, p=0.0159) compared to control 2. This establishes mFOLFOX6 as an effective first-line regimen.

For bowel cleansing in colonoscopy, NER1006 with 2-day split-dosing showed significantly better 'excellent plus good' cleansing in the ascending colon (p<0.001) compared to control, though overall successful cleansing and adenoma detection rates were not significantly different 4. Day-before-only dosing of NER1006 also showed significant improvement in overall successful cleansing (p=0.038) and ascending colon cleansing (p=0.027) 6. However, another trial of NER1006 (2-day split) found no significant differences in overall cleansing or adenoma detection 5, indicating mixed evidence for some endpoints.

In a phase 2 trial, pembrolizumab achieved a disease control rate of 13% at 4 months in previously treated colorectal cancer patients 10. Another phase 2 trial of pembrolizumab (N=124) is listed as established but no outcome data are provided 12.

A phase 3 trial of BBI608 in advanced colorectal cancer found no significant benefit in overall survival (4.44 vs. 4.76 months, p=0.337), progression-free survival (1.82 vs. 1.82, p=0.837), or disease control rate (17% vs. 18%, p=0.955) 3.

Goal-directed fluid optimization in a phase 4 trial (N=58) is listed as established, but no outcome data are provided 1.

Recent results — preliminary, needs further review

  • A phase 2 trial of nivolumab (N=325) is recent, but no outcome data are provided 7.
  • A phase 2 trial of NUC-3373 plus leucovorin (N=111) reported percentage change from baseline in tumour size, but results are unconfirmed 8.
  • A phase 2 trial of durvalumab (N=34) reported adverse events and 5-month progression-free survival, but results are unconfirmed 9.
  • A phase 2 trial of JX-594 (N=52) is recent, but no outcome data are provided 11.
  • A phase 2 trial of enzastaurin (N=26) found no significant differences in PFS at 6 months (p=0.431), tumor response (p=0.593), or duration of response (p=0.157) 13.

For the clinician treating this condition

  • mFOLFOX6 significantly improves PFS, OS, and ORR in metastatic colorectal cancer 2.
  • NER1006 may improve bowel cleansing in the ascending colon, but overall adenoma detection rates are not consistently improved 46.
  • BBI608 showed no benefit in advanced colorectal cancer 3.
  • Pembrolizumab has modest activity in a phase 2 setting 10.

AI synthesis of 13 cited trials, updated Aug 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
PGE2 signaling via EP receptors drives tumor progression and context-dependent neuroinflammation in various diseases
Drug Pipeline Sys. Review
PGE2 signaling via EP receptors drives tumor progression and context-dependent neuroinflammation in various diseases Understanding the Role of PGE2 Signaling in Brain Health and Cancer
This systematic review examines the role of PGE2 signaling across neurological, oncological, and metabolic conditions. The findings indicate…
New research shows how different parts of a single protein pathway can either protect your brain or help tumors grow.
Frontiers Aug 23, 2026